Deep Dive: Page 3

Industry insights from our journalists


  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    A flashy 2019 start to pharma M&A, but will it last?

    Recent high-profile acquisitions don't fully clear up what the buyer's market will look like in an expected bumper year for dealmaking.

    Jacob Bell • Jan. 22, 2019
  • How a 'regulatory dead zone' may be holding up copycat insulin

    The FDA has talked up biosimilars' potential impact on the insulin market, but changing regulations have complicated matters for would-be competitors.

    Andrew Dunn • Jan. 14, 2019
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    At JPM, the NASH flood gates start to crack

    Multiple late-stage results are slated for 2019, bringing to the forefront a question of how battle lines will be drawn across the market.

    Jacob Bell • Jan. 11, 2019
  • story image
    Image attribution tooltip
    Getty Images

    Hunting productivity, drugmakers pitch new 'pillars' of R&D

    By some measures, returns on R&D have fallen to decade lows. Pharmas and biotechs, however, argue new technologies could open faster paths to market. 

    Ned Pagliarulo • Jan. 11, 2019
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    3 questions leaving ASH

    Like many a medical meeting, ASH showcased data that — while promising — also offers as many questions as answers.

    Jacob Bell • Dec. 5, 2018
  • story image
    Image attribution tooltip
    Jacob Bell / BioPharma Dive

    At ASH, bispecific cancer therapies make a mark

    The therapies work to guide tumor-fighting immune cells to target cancerous invaders. Research at ASH suggests they could be another avenue of attack in immuno-oncology.

    Ned Pagliarulo and Jacob Bell • Dec. 5, 2018
  • Executive of the Year: Emma Walmsley, GlaxoSmithKline

    Since taking the helm, Walmsley has launched an R&D restructure, shaken up GSK's top leadership and reset a corporate strategy that's failed to deliver industry-leading growth.

    Ned Pagliarulo • Dec. 3, 2018
  • story image
    Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Memorial Sloan Kettering scandal raises questions for pharma's biggest corporate boards

    A review of corporate board membership found about two-thirds of the largest drugmakers had at least one director who also had a leadership role in a nonprofit healthcare organization.

    Andrew Dunn • Nov. 29, 2018
  • story image
    Image attribution tooltip
    Gilead Sciences Inc.

    Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.

    The therapy lags its competitors in getting to market, but clinical data could make filgotinib stand out. How much would a late arrival hurt its prospects?

    Andrew Dunn • Nov. 26, 2018
  • story image
    Image attribution tooltip
    Yugin Kim / BioPharma Dive

    Red pill or blue? It could be a billion-dollar decision

    Viagra and Nexium ​underscore how marketers and manufacturers can use color to make a drug franchise more successful.

    Jacob Bell • Oct. 29, 2018
  • story image
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive

    First Amendment takes center stage in DTC price fight

    A string of court decisions have bolstered commercial speech rights for industry. The Trump administration's push to require prices in TV ads could become the next legal battleground.

    Andrew Dunn • Oct. 22, 2018
  • story image
    Image attribution tooltip
    Yujin Kim / BioPharma Dive

    Pharma's slow embrace of continuous manufacturing

    On the whole, drugmakers remain wedded to traditional production methods that have served for decades. Some, however, are shifting to newer technology.

    Ned Pagliarulo • Sept. 24, 2018
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    For CDMOs, continuous manufacturing isn't an 'if,' but a 'how'

    Contract services providers are receiving more interest from drugmakers keen on the technology's potential cost-savings and better efficiency.

    Jacob Bell • Sept. 24, 2018
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    As FDA and pharma warm to continuous manufacturing, generics stay skeptical

    Generics companies worry continuous manufacturing could become another tool for branded drugmakers to protect their products.

    Andrew Dunn • Sept. 24, 2018
  • FDA confronts its limits in push on drug pricing

    Legally, regulating prices is outside of the FDA's purview. But that hasn't stopped Scott Gottlieb from taking a more vocal approach to the hot-button issue than past FDA chiefs.

    Ned Pagliarulo • Aug. 27, 2018
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    FDA ups the ante for copycats, antibiotics, orphan drugs. But is it working?

    Regulators are using incentives to spur development of much-needed drugs. The results so far have been mixed.

    Jacob Bell • Aug. 27, 2018
  • story image
    Image attribution tooltip
    Credit: Andrew Propp, FDA / Edited by BioPharma Dive

    How Scott Gottlieb is upending FDA communication, one tweet at a time

    The FDA commissioner has relentlessly pumped out tweets, statements and more. But how has that affected FDA communications and the agency overall?

    Andrew Dunn • Aug. 27, 2018
  • story image
    Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Seeking to adopt AI, drugmakers search for right mix of talent

    AI holds promise as a powerful new tool in the hunt for new drugs. Yet building a team that blends tried-and-true methods with AI remains a challenge.

    Ned Pagliarulo • July 23, 2018
  • story image
    Image attribution tooltip
    Credit: Getty / Edited by BioPharma Dive

    Payers, doctors weigh AI's disruptive prescribing potential

    The disruption won't happen overnight, though, as big tech firms try to not only develop healthcare AI tools, but show they'll enhance, rather than upend, the doctor-patient relationship.

    Jacob Bell • July 23, 2018
  • story image
    Image attribution tooltip
    Getty Images

    Immunotherapy advances spur new look at cancer vaccines

    Researchers have long been intrigued by the idea of a cancer vaccine, drawn in by hints of an immune role in cases of "spontaneous" remissions to cancer.  Now, the immunotherapy boom is opening up new areas of research.

    Ned Pagliarulo • June 25, 2018
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    Why be a vaccine company?

    Lower margins and pricey manufacturing are hallmarks of vaccine making. Yet the drugs can provide a steady, and often competition-free, source of revenue.

    Jacob Bell • June 25, 2018
  • story image
    Image attribution tooltip
    Chris Garabedian | Xontogeny

    Garabedian has few regrets and is ready to be seen

    The former embattled Sarepta CEO is attempting a comeback by exploring a different facet of an industry he knows well. 

    Lisa LaMotta • June 11, 2018
  • story image
    Image attribution tooltip
    Getty Images: Edited by BioPharma Dive

    Pharma turn to NASH unlikely to mirror meteoric rise of hep C

    Hopes of a hepatitis C-sized market could be dashed by the complexity of and challenges in diagnosing the lesser-known liver disease. 

    Ned Pagliarulo • May 21, 2018
  • story image
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    After a flurry, NASH deals put on pause

    After several years of dealmaking in the liver disease space, the industry waits for the next wave of assets to mature. 

    Lisa LaMotta • May 21, 2018
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    NASH drug pipeline headed toward uncertain market

    The fatty liver disease has dozens of treatments in the global pipeline. But investors are treading lightly, casting doubt on the market opportunity.

    Jacob Bell • May 21, 2018